| Prev Close: | 2.49 |
|---|---|
| Open: | N/A |
| Bid: | 2.35 |
| Ask: | 2.50 |
| 1y Target Est: | N/A |
| Beta: | N/A |
| Next Earnings Date: | 28-May-13 |
| Day's Range: | N/A - N/A |
|---|---|
| 52wk Range: | 0.97 - 3.99 |
| Volume: | 0 |
| Avg Vol (3m): | 5,042 |
| Market Cap: | 107.69M |
| P/E (ttm): | N/A |
| EPS (ttm): | N/A |
| Div & Yield: | N/A (N/A) |
Quotes delayed, except where indicated otherwise. Currency in CAD.
Headlines
- Registry Data Presented at EuroPCR 2013 Confirms the Neovasc Reducer™ Improves Cardiovascular Parameters in Refractory Angina PatientsCNW Group(Tue May 21)
- Registry Data Presented at EuroPCR 2013 Confirms the Neovasc Reducer™ Improves Cardiovascular Parameters in Refractory Angina PatientsPR Newswire(Tue May 21)
- Registry Data Presented at EuroPCR 2013 Confirms the Neovasc Reducer™ Improves Cardiovascular Parameters in Refractory Angina PatientsCNW Group(Tue May 21)
- Neovasc Inc. Completes Enrollment in COSIRA Trial Assessing Efficacy of Reducer™ Product for Treatment of Refractory AnginaCNW Group(Mon May 13)
- Neovasc Inc. Completes Enrollment in COSIRA Trial Assessing Efficacy of Reducer™ Product for Treatment of Refractory AnginaPR Newswire(Mon May 13)
- Neovasc Inc. Completes Enrollment in COSIRA Trial Assessing Efficacy of Reducer™ Product for Treatment of Refractory AnginaCNW Group(Mon May 13)
- Neovasc Inc. reports financial results for 2012 year-endCNW Group(Mon Apr 29)
- Neovasc Inc. reports financial results for 2012 year-endPR Newswire(Mon Apr 29)
- Neovasc Inc. reports financial results for 2012 year-endCNW Group(Mon Apr 29)
- Q4 2012 Neovasc Inc Earnings Release - Time Not SuppliedCCBN(Mon Apr 29)
- Neovasc Inc. reports exercise of 1.8 million warrants for net proceeds of $2.3 millionCNW Group(Thu Apr 25)
- Neovasc Inc. reports exercise of 1.8 million warrants for net proceeds of $2.3 millionCNW Group(Thu Apr 25)
- Neovasc's COSIRA clinical trial protocol selected for publication in peer-reviewed journalCNW Group(Thu Feb 28)
- Neovasc's COSIRA clinical trial protocol selected for publication in peer-reviewed journalPR Newswire(Thu Feb 28)
- Neovasc's COSIRA clinical trial protocol selected for publication in peer-reviewed journalCNW Group(Thu Feb 28)
Press Releases
- Registry Data Presented at EuroPCR 2013 Confirms the Neovasc Reducer™ Improves Cardiovascular Parameters in Refractory Angina PatientsCNW Group(Tue May 21)
- Neovasc Inc. Completes Enrollment in COSIRA Trial Assessing Efficacy of Reducer™ Product for Treatment of Refractory AnginaCNW Group(Mon May 13)
- Neovasc Inc. reports financial results for 2012 year-endCNW Group(Mon Apr 29)
Must Read
- Clearwire recommends vote for revised Sprint bidReuters(Wed 5:20AM EDT)
- Target's 1st-qtr profit drops 26 pct on weak sales as weather, financial pressures take tollThe Canadian Press(Wed 5:16AM EDT)
- Loonie heads lower ahead of speech by U.S. Federal Reserve chairman Ben BernankeThe Canadian Press(Wed 4:54AM EDT)
- Pfizer to spin off Zoetis stake to shareholdersReuters(Wed 4:52AM EDT)
- Wall Street headed for a solid open ahead of speech by Ben BernankeThe Canadian Press(Wed 4:49AM EDT)